MyFinsight
Home
Blog
About
Net proceeds from
exercise of warrants and...
$9,730,818
Net proceeds from
notes payable
$9,635,000
Net cash provided by
financing activities
$18,641,701
Canceled cashflow
$724,117
Net change in cash
and cash...
$13,931,071
Canceled cashflow
$4,710,630
Deferred financing costs
$723,299
Net proceeds from
issuance of common stock
-$818
Stock-based compensation
expense
$3,560,791
(-40.87%↓ Y/Y)
Due to related party
$1,764,072
(-74.34%↓ Y/Y)
Amortization of in-process
research and development
$1,720,312
Accounts receivable, net
of allowances
-$392,820
Prepaid expenses
-$221,107
(86.18%↑ Y/Y)
Amortization of deferred
financing costs
$179,492
Inventory
-$33,645
(-100.38%↓ Y/Y)
Accrued expenses
$16,047
(-99.81%↓ Y/Y)
Net cash (used in)
provided by operating...
-$2,710,630
Net cash used in
investing activities
-$2,000,000
Canceled cashflow
$7,888,286
Net loss
-$8,923,846
(54.85%↑ Y/Y)
License payments
$2,000,000
Accounts payable
-$1,567,723
(-131.63%↓ Y/Y)
Deferred income tax
expense
-$107,347
(-113.54%↓ Y/Y)
Back
Back
Cash Flow
CITIUS ONCOLOGY, INC. (CTOR)
CITIUS ONCOLOGY, INC. (CTOR)
source: myfinsight.com